The Caledonian Record2d
Trump commerce pick says favors broad tariffs, vows tough China stance
Donald Trump's commerce secretary nominee told his US Senate confirmation hearing Wednesday he favors "across-the-board" tariffs targeting countries rather than products, while signaling a hawkish ...
Cantor Fitzgerald Reaffirms Their Buy Rating on Cigna (CI)
Cantor Fitzgerald analyst Sarah James maintained a Buy rating on Cigna (CI – Research Report) yesterday and set a price target of $350.00. The ...
Fintel on MSN14h
Cantor Fitzgerald Initiates Coverage of Acrivon Therapeutics (ACRV) with Overweight Recommendation
Fintel reports that on January 31, 2025, Cantor Fitzgerald initiated coverage of Acrivon Therapeutics (NasdaqGM:ACRV) with a Overweight recommendation. Analyst Price Forecast Suggests 260.44% Upside ...
Cantor Fitzgerald Holds Tether Convertible Bond, Howard Lutnick Says
Cantor Fitzgerald has a convertible bond with Tether, incoming Commerce Secretary Howard Lutnick said at his confirmation hearing, confirming previous reporting by The Wall Street Journal that ...
Intel (INTC) Receives a Hold from Cantor Fitzgerald
Cantor Fitzgerald analyst C J Muse maintained a Hold rating on Intel (INTC – Research Report) yesterday and set a price target of $22.00. The ...
Cantor Fitzgerald Suit Against Ex-Bankers’ Firm Is Dismissed
Cantor Fitzgerald LP’s lawsuit alleging a firm founded by four of its former investment bankers stole clients worth millions of dollars in profit was dismissed by a New York judge.
Cantor Fitzgerald Upgrades Zevra Therapeutics (NASDAQ:ZVRA) to Strong-Buy
Cantor Fitzgerald upgraded shares of Zevra Therapeutics (NASDAQ:ZVRA – Free Report) to a strong-buy rating in a research note issued to investors on Wednesday,Zacks.com reports. Other equities ...
Hosted on MSN2d
Cantor Fitzgerald Upgrades Beam Therapeutics (BEAM)
Fintel reports that on January 29, 2025, Cantor Fitzgerald upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from Neutral to Overweight. Analyst Price Forecast Suggests 87.91% Upside As of ...
ETF Daily News4d
Cantor Fitzgerald Comments on Sanara MedTech FY2024 Earnings
Cantor Fitzgerald currently has a “Overweight” rating and a $44.00 price objective on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.33) per share.
The Real Deal4d
Flagstar, formerly NYCB, dumps $142M in rent-stabilized loans
This month, Flagstar offloaded $142 million of that portfolio, finding a buyer in Howard Lutnick’s Cantor Fitzgerald, PincusCo reported. A spokesperson for Cantor Fitzgerald did not return a ...
Investing5d
Cantor Fitzgerald maintains Overweight on Western Digital stock
On Monday, analysts at Cantor Fitzgerald reaffirmed their Overweight rating on Western Digital Corp. (NASDAQ:WDC) shares, with a steady price target of $95.00. According to InvestingPro data ...